Navigation Links
Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Date:11/18/2008

ed on days 1, 3 and 5. The target enrollment is 120 patients. The primary endpoint of the study is complete remission rate. Secondary endpoints are duration of complete remission, time to treatment failure, survival at 12 months, 30, 60, and 90 day mortality and safety and tolerability.

Interim Phase 1 data with CPX-351, where complete remissions were obtained in patients with advanced leukemia, were reported in December 2007. Additional Phase 1 and preclinical data were accepted for presentation at the upcoming American Society of Hematology (ASH) meeting in San Francisco in December.

  • Phase 1 Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias will be presented on Monday, December 8, 2008, 5:30PM to 7:30PM in the Moscone Center, Hall A.

  • Synergistic Cytarabine:Daunorubicin Ratios Delivered by CPX-351 to Human Leukemia Xenografts is Associated with Liposome-Mediated Bone Marrow Drug Accumulation, Intracellular Delivery of Encapsulated Agents to Leukemia Cells, and Increased Efficacy will be presented on Saturday, December 6, 2008, 5:30PM to 7:30PM in the Moscone Center, Hall A.

"This is an important milestone for Celator and we are excited about the benefit CPX-351 may offer patients," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "We continue to open new clinical trial sites for participation in this study and we are moving forward with a second randomized Phase 2 study in patients with AML in first relapse."

About Acute Myeloid Leukemia (AML)

The National Cancer Institute defines AML as a quickly progressing disease in which too many immature white blood cells (not lymphocytes) are found in the blood and bone marrow. In 2008, the A
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
4. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
5. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Raptor Pharmaceuticals Provides Update on Targeting Platforms

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...c. 2 Novartis announced today that...on Tasigna® (nilotinib) 200 mg capsules in a ...strength of the company,s hematology portfolio in ...a, at the 51st American Society of Hematology (ASH...pany,s current therapies and investigational agent...
(Date:12/1/2009)...wire/ -- Reportlinker.com announces that a new mar... ,, Medical Oxygen Systems - Global Market Op...0164334/Medical-Oxygen-Systems---Global-Market-Opp...stems market for home healthcare setting is reckon...wth expectations stem from demographic factors suc...
(Date:12/1/2009)...wire/ -- Reportlinker.com announces that a new mar... ,, Molecular Diagnostics - A World Market Rev...olecular-Diagnostics---A-World-Market-Review.html ...n by several growth factors that include the need ... combine optimized sample preparation, analysis, a...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 2Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 3Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 4Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 5Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 6Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 7Reportlinker Adds Molecular Diagnostics - A World Market Review 2Reportlinker Adds Molecular Diagnostics - A World Market Review 3Reportlinker Adds Molecular Diagnostics - A World Market Review 4Reportlinker Adds Molecular Diagnostics - A World Market Review 5Reportlinker Adds Molecular Diagnostics - A World Market Review 6OneDotOneLife org Saving the Lives of More Than 2 Million Children 5048 1OneDotOneLife org Saving the Lives of More Than 2 Million Children 5048 2Pres Clinton Announces Commitment From Inter American Development Bank Global Network for Neglected Tropical Diseases and Pan American Health Organ 5046 1Pres Clinton Announces Commitment From Inter American Development Bank Global Network for Neglected Tropical Diseases and Pan American Health Organ 5046 2Pres Clinton Announces Commitment From Inter American Development Bank Global Network for Neglected Tropical Diseases and Pan American Health Organ 5046 3Regence to Cover Administration Costs of H1N1 Vaccine for Fully Insured Groups Individuals This Flu Season 5044 1Regence to Cover Administration Costs of H1N1 Vaccine for Fully Insured Groups Individuals This Flu Season 5044 2Regence to Cover Administration Costs of H1N1 Vaccine for Fully Insured Groups Individuals This Flu Season 5044 3
...J., Oct. 29 Sanofi-aventis,announced today that t...d,Apidra(R) (insulin glulisine [rDNA origin] injec...ears and older) with diabetes mellitus., The appr...FDA review of,a 26-week, phase III, open-label, ac... insulin lispro, in 572 children and adolescents (...
..., Oct. 29 CuraGen Corporation,(Nasdaq: CRGN ), a...on,oncology, announced today that Company executiv...t 11:00 a.m. ET on Monday, November 3, 2008,follow...sults and to review,preliminary data from CuraGen,...for the treatment of advanced melanoma., Data fro...
Other Medicine Technology:FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 2FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 3FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 4FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 5CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008 2
(Date:12/2/2009)..., A team of Kendall Hunt ...er of the Year Award at the recent National Associ...e in St. Louis, November 5-7, 2009. , ...-- A team of Kendall Hunt authors earned the 2009 ...the recent National Association for Gifted Childre...
(Date:12/2/2009)..., , Ad in Today,s Washington Post ...ewswire-USNewswire/ -- If the Catholic bishops ...tative measures we take for granted may be under t...ght to bear on the debate over healthcare reform h...Washington Post warns of the likely impact if tha...
(Date:12/2/2009)... Insect repellents suspected in birth defect that ..., WEDNESDAY, Dec. 2 (HealthDay News) -- Male babie...rst three months of pregnancy appear to be at incr...researchers report. , This birth defect, which ...ves premature shortening of the urethra, the tube ...
(Date:12/2/2009)..., , Fruit flies may seem like unlikely heroes in ...ggests that these insects already used to study d...entists are reporting that fruit flies can be used... studying the effects of cocaine and other drugs o...n ACS Chemical Neuroscience , a new monthly journ...
(Date:12/2/2009)..., MyCareTeam, Inc., a lea...gement software, has released the newest version o...udes hypertension, congestive heart failure and we...isting diabetes monitoring features. , ...9 -- MyCareTeam, Inc., a leading vendor of Interne...
Breaking Medicine News(10 mins):Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure 2
...our out of five hospitalized children receive medi...r adults//. The authors fear that treating childre...omes. "We measured the magnitude of off-labe...hiladelphia. "Given the nature of the available da...
...in Nigeria has been a success, but continued commi...icate the virus from northern states, say official...ive was launched in May 2006 by the National Progr...egions still affected by the virus. People i...
...ly diagnosis of lung cancer. They hope the analysi.../ lining the airways leading to the lungs can be u...s more effective. Lung cancer is the most dead...d and nearly 29,000 deaths. Part of the reas...
...sults of a study showing clearly that soft drinks ...gher body weight, a decrease in calcium and other ... The report also noted that studies funded b...le analyzed 88 previously published studies obtain...
...e accurate amount of fat in a human body, accordin... as the standard for measuring the amount of fat i...'s body weight divided by the square of their heig... at a greater risk of heart disease, diabetes and ...
...on educated in India, was Monday conferred with th... Ruit has conducted over 70,000 surgeries fo...indness in the subcontinent. "It is an apt a...d surgeon at the award ceremony here. Ruit h...
Other Medicine News:Health News:Prescribing Off Label Drugs for Children may Be Hazardous 2Health News:Prescribing Off Label Drugs for Children may Be Hazardous 3Health News:Nigerian Programme Increases Polio Immunisation 2Health News:Gene Cell Test may Aid Early Lung Cancer Diagnosis 2Health News:Yale Researchers Weigh the Science on Soft Drinks and Health 2
...rade; is a pressure relief mattress overlay design...ow air loss therapy for those patient with skin br...ONS: , Patients whose body weight and size pose a...patient or staff during the performance of routine...
...providing a flexible environment for patient care,... comfort, support, treatment and prevention., ,IN... ,Large patients at risk for pressure ulcers ,Any ...enefit from a pressure reduction surface ,Patients...
Triflex™ II Bariatric Bed
...sty Max 10 Nebulizer W/ 7` CR Resistant Oxygen Tub...times , ,Provide fine particles with a tighter di...les) than conventional nebulizers, ,Our AirLife&t...ers deliver fast and effective treatment more effi...
Medicine Products: